Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Neurosci Res. 2015 Jul 8;93(10):1592–1599. doi: 10.1002/jnr.23622

Figure 1. Effects of dopamine receptor agonists on synaptic ERK1/2 phosphorylation in the rat forebrain.

Figure 1

(A) Effects of SKF81297 and quinpirole on ERK1/2 phosphorylation in the striatum. (B) Effects of SKF81297 and quinpirole on ERK1/2 phosphorylation in the mPFC. Two bands were typically observed for pERK1/2 and ERK1/2 signals (upper bands = pERK1 and ERK1 with 44 kDa; lower bands = pERK2 and ERK2 with 42 kDa). Note a significant increase in pERK2 levels in both forebrain regions in SKF81297- but not quinpirole-treated rats. Representative immunoblots are shown left of the quantified data. Rats received a single dose of SKF81297 (3 mg/kg, i.p.) or quinpirole (3 mg/kg, i.p.) and were sacrificed 20 min after drug injection for immunoblot analysis with synaptosomal proteins. The pERK2 data were analyzed with one-way analysis of variance: F(2,15) = 8.3, n = 18, P < 0.05 and F(2,12) = 7.7, n = 15, P < 0.05, respectively in the striatum and mPFC. The ERK2 data were also analyzed with one-way analysis of variance: F(2,15) = 0.92, n = 18, P > 0.05 and F(2,12) = 0.76, n = 15, P > 0.05, respectively in the striatum and mPFC. Data are presented as means ± SEM (n = 5-6 per group). *P < 0.05 versus saline.

HHS Vulnerability Disclosure